CERE vs. ITCI, VKTX, JAZZ, CYTK, ASND, ELAN, LEGN, ROIV, IONS, and APLS
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Ascendis Pharma A/S (ASND), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Roivant Sciences (ROIV), Ionis Pharmaceuticals (IONS), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Cerevel Therapeutics (NASDAQ:CERE) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Intra-Cellular Therapies received 348 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 67.34% of users gave Intra-Cellular Therapies an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
Cerevel Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Cerevel Therapeutics has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -30.08%. Intra-Cellular Therapies' return on equity of -23.02% beat Cerevel Therapeutics' return on equity.
Intra-Cellular Therapies has higher revenue and earnings than Cerevel Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Cerevel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cerevel Therapeutics currently has a consensus target price of $41.40, indicating a potential downside of 2.36%. Intra-Cellular Therapies has a consensus target price of $90.17, indicating a potential upside of 23.23%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Intra-Cellular Therapies is more favorable than Cerevel Therapeutics.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Intra-Cellular Therapies had 19 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 22 mentions for Intra-Cellular Therapies and 3 mentions for Cerevel Therapeutics. Cerevel Therapeutics' average media sentiment score of 0.64 beat Intra-Cellular Therapies' score of 0.57 indicating that Cerevel Therapeutics is being referred to more favorably in the media.
Summary
Intra-Cellular Therapies beats Cerevel Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cerevel Therapeutics Competitors List
Related Companies and Tools
